PDF(Pubmed)
Abstract：
UNASSIGNED: To perform a dosimetric and a normal tissue complication probability (NTCP) comparison between intensity modulated proton therapy and photon volumetric modulated arc therapy in a cohort of patients with parotid gland cancers in a post-operative or radical setting.
UNASSIGNED: From May 2011 to September 2021, 37 parotid gland cancers patients treated at two institutions were eligible. Inclusion criteria were as follows: patients aged ⩾ 18 years, diagnosis of parotid gland cancers candidate for postoperative radiotherapy or definitive radiotherapy, presence of written informed consent for the use of anonymous data for research purposes. Organs at risk (OARs) were retrospectively contoured. Target coverage goal was defined as D95 > 98%. Six NTCP models were selected. NTCP profiles were calculated for each patient using an internally-developed Python script in RayStation TPS. Average differences in NTCP between photon and proton plans were tested for significance with a two-sided Wilcoxon signed-rank test.
UNASSIGNED: Seventy-four plans were generated. A lower Dmean to the majority of organs at risk (inner ear, cochlea, oral cavity, pharyngeal constrictor muscles, contralateral parotid and submandibular gland) was obtained with intensity modulated proton therapy vs volumetric modulated arc therapy with statistical significance (p < .05). Ten (27%) patients had a difference in NTCP (photon vs proton plans) greater than 10% for hearing loss and tinnitus: among them, seven qualified for both endpoints, two patients for hearing loss only, and one for tinnitus.
UNASSIGNED: In the current study, nearly one-third of patients resulted eligible for proton therapy and they were the most likely to benefit in terms of prevention of hearing loss and tinnitus.
UNASSIGNED: From May 2011 to September 2021, 37 parotid gland cancers patients treated at two institutions were eligible. Inclusion criteria were as follows: patients aged ⩾ 18 years, diagnosis of parotid gland cancers candidate for postoperative radiotherapy or definitive radiotherapy, presence of written informed consent for the use of anonymous data for research purposes. Organs at risk (OARs) were retrospectively contoured. Target coverage goal was defined as D95 > 98%. Six NTCP models were selected. NTCP profiles were calculated for each patient using an internally-developed Python script in RayStation TPS. Average differences in NTCP between photon and proton plans were tested for significance with a two-sided Wilcoxon signed-rank test.
UNASSIGNED: Seventy-four plans were generated. A lower Dmean to the majority of organs at risk (inner ear, cochlea, oral cavity, pharyngeal constrictor muscles, contralateral parotid and submandibular gland) was obtained with intensity modulated proton therapy vs volumetric modulated arc therapy with statistical significance (p < .05). Ten (27%) patients had a difference in NTCP (photon vs proton plans) greater than 10% for hearing loss and tinnitus: among them, seven qualified for both endpoints, two patients for hearing loss only, and one for tinnitus.
UNASSIGNED: In the current study, nearly one-third of patients resulted eligible for proton therapy and they were the most likely to benefit in terms of prevention of hearing loss and tinnitus.
摘要：
■在腮腺癌术后或根治性治疗的一组患者中，进行强度调节质子治疗和光子体积调节电弧治疗之间的剂量学和正常组织并发症概率（NTCP）比较。
■从2011年5月到2021年9月，在两个机构接受治疗的37名腮腺癌患者符合资格。纳入标准如下：18岁的患者，腮腺癌的诊断为术后放疗或明确放疗的候选人，存在用于研究目的的匿名数据的书面知情同意书。对危险器官(OAR)进行回顾性轮廓分析。目标覆盖率目标定义为D95>98%。选择了六个NTCP模型。使用RayStationTPS中内部开发的Python脚本计算每位患者的NTCP概况。用双侧Wilcoxon符号秩检验测试了光子和质子计划之间NTCP的平均差异的显著性。
■生成了74个计划。对大多数处于危险中的器官(内耳，耳蜗,口腔,咽缩肌,对侧腮腺和颌下腺）采用强度调节质子治疗与体积调节电弧治疗，具有统计学意义（p<.05）。10名（27%）患者的NTCP（光子与质子计划）在听力损失和耳鸣方面的差异大于10%：其中，七个合格的两个端点，只有两名听力损失患者，还有一个是耳鸣.
■在当前的研究中，近三分之一的患者符合质子治疗的条件,他们最有可能在预防听力损失和耳鸣方面获益.
■从2011年5月到2021年9月，在两个机构接受治疗的37名腮腺癌患者符合资格。纳入标准如下：18岁的患者，腮腺癌的诊断为术后放疗或明确放疗的候选人，存在用于研究目的的匿名数据的书面知情同意书。对危险器官(OAR)进行回顾性轮廓分析。目标覆盖率目标定义为D95>98%。选择了六个NTCP模型。使用RayStationTPS中内部开发的Python脚本计算每位患者的NTCP概况。用双侧Wilcoxon符号秩检验测试了光子和质子计划之间NTCP的平均差异的显著性。
■生成了74个计划。对大多数处于危险中的器官(内耳，耳蜗,口腔,咽缩肌,对侧腮腺和颌下腺）采用强度调节质子治疗与体积调节电弧治疗，具有统计学意义（p<.05）。10名（27%）患者的NTCP（光子与质子计划）在听力损失和耳鸣方面的差异大于10%：其中，七个合格的两个端点，只有两名听力损失患者，还有一个是耳鸣.
■在当前的研究中，近三分之一的患者符合质子治疗的条件,他们最有可能在预防听力损失和耳鸣方面获益.
